

Franklin Biotechnology Discovery Fund

LU0109394709

Sector | Factsheet as of 31 December 2025

This is a marketing communication. Please refer to the offering documents before making any final investment decisions.

Risk Considerations

INVESTMENT INVOLVES RISKS. The value of the Fund can be volatile and investors may not get back the amount originally invested. Past performance is not indicative of future results.

- Franklin Biotechnology Discovery Fund invests principally in equity securities issued by biotechnology companies in the U.S. and other countries.
- The Fund is subject to market risk, equity risk, foreign currency risk, liquidity risk, biotechnology, communication and technology sectors risk, debt securities risk, concentration risk, smaller and midsize companies risk, growth stocks risk, counterparty risk, Private Investments in Public Equity risk, private companies risk, special purpose acquisition companies risk and derivative instruments risk.
- Security lending transactions may involve the risk that the borrower may fail to return the securities lent out in a timely manner and the value of the collateral may fall below the value of the securities lent out, which may result in a substantial loss to the Fund.
- The Fund may at its discretion pay dividends out of the capital or out of gross income of the Fund while paying all or part of the Fund's fees and expenses out of the capital of the Fund, which results in effectively paying dividends out of capital. Payment of dividends out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any distributions involving payment of dividends out of the Fund's capital or payment of dividends effectively out of the Fund's capital (as the case may be) may result in an immediate reduction of the net asset value per share.
- Investors should not invest based on this marketing material alone. Offering documents should be read for further details, including the risk factors. Before you decide to invest, you should make sure the intermediary has explained to you that the Fund is suitable to you.

Past performance does not predict future returns.

Performance Over 5 Years in Share Class Currency (%)

■ Franklin Biotechnology Discovery Fund - A (acc) USD



Total Returns (%)

	Cumulative						Annualised				Inception Date
	1-Mo	3-Mo	YTD	1-Yr	3-Yr	5-Yr	Inception	3-Yr	5-Yr	Inception	
A (acc) USD	-1.66	23.43	51.13	51.13	81.95	31.55	493.15	22.08	5.64	7.16	3/4/2000
Benchmark (USD)	-1.90	16.95	32.40	32.40	35.46	19.92	435.74	10.64	3.70	6.74	—

Calendar Year Returns (%)

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
A (acc) USD	51.13	2.64	17.29	-12.51	-17.36	27.52	33.53	-16.31	16.93	-17.87
Benchmark (USD)	32.40	-1.37	3.74	-10.91	-0.63	25.69	24.41	-9.32	21.06	-21.68

Investment Objective

To seek long-term investment growth, through growth of capital. The Fund mainly invests in equities of biotechnology companies and discovery research firms of any market capitalisation. This may include companies involved with genomics, genetic engineering and gene therapy as well as companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. These investments may be from anywhere in the world, although the Fund may invest significantly in the US.

Morningstar Rating™

Overall Rating as of 31 December 2025

★★★★ A (acc) USD

Fund Overview

Umbrella	Franklin Templeton Investment Funds
Fund Base Currency	USD
Fund Inception Date	03/04/2000
Share Class Inception Date	03/04/2000
Minimum Investment (USD)	1000
ISIN	LU0109394709
Bloomberg	TEMBDAI LX
Morningstar Peer Group	Sector Equity Biotechnology
EU SFDR Category	Article 8

Benchmark(s) and Type

NASDAQ Biotechnology Index	Comparator
----------------------------	------------

Fund Characteristics

	Fund
NAV-A (acc) USD	\$59.32
Total Net Assets (USD)	\$1.82 Billion
Number of Issuers	80
Average Market Cap (Millions USD)	\$58,441
Historical EPS Growth (3 Yr)	-11.17%
Standard Deviation (3 Yr)	20.39%

Top Equity Issuers (% of Total)

	Fund
GILEAD SCIENCES INC	5.17
JAZZ PHARMACEUTICALS PLC	4.57
REGENERON PHARMACEUTICALS INC	4.48
AMGEN INC	4.47
VERTEX PHARMACEUTICALS INC	4.41
ARGENX SE	3.91
PRAXIS PRECISION MEDICINES INC	3.27
INSMED INC	3.12
TERNS PHARMACEUTICALS INC	3.00
ALNYLAM PHARMACEUTICALS INC	2.80

Sector Allocation (% of Total)

	Fund
Biotechnology	75.67
Pharmaceuticals	17.30
Health Care Services	2.42
Life Sciences Tools & Services	1.07
Managed Health Care	0.25
Cash & Cash Equivalents	3.29

Market Cap Breakdown (% of Equity) (USD)

	Fund
<2.0 Billion	20.88
2.0-5.0 Billion	16.50
5.0-10.0 Billion	8.48
10.0-25.0 Billion	19.63
25.0-50.0 Billion	3.69
>50.0 Billion	30.04
N/A	0.77

Share Class Details

	ISIN	Max. Initial Charge	Annual Charge	Dividends	
				Payable Date	Amount
A (acc) USD	LU0109394709	5.00%	1.50%	—	—
A (acc) HKD	LU0889565916	5.00%	1.50%	—	—
Only dividend records within the past 12 months are displayed. Dividend amounts are quoted in the currency of the respective share class. Annual Charge includes Management Fee and Maintenance Charge.					

Portfolio Management

	Years with Firm	Years of Experience
Evan McCulloch, CFA	33	33
Akiva Felt	7	18

Glossary

Comparator: Benchmark is used for comparing Fund performance, but is not a constraint to Fund Investment. **Weighted Average Market Capitalization:** A determination of a company's value, calculated by multiplying the total number of company stock shares outstanding by the price per share. For a portfolio, the value represents a weighted average based on the stocks held. **Historical 3 Yr EPS Growth:** A measure of the growth of earnings per share over a trailing 3 year period. For a portfolio, the value represents a weighted average of the stocks it holds. **Standard Deviation:** Measure of the degree to which a fund's return varies from the average of its previous returns. The larger the standard deviation, the greater the likelihood (and risk) that a fund's performance will fluctuate from the average return. **Charges:** For a comprehensive list of the types of costs deducted from fund assets, see the prospectus and Product Key Facts.

Portfolio Data Information

Holdings are provided for information purposes only and should not be deemed a recommendation to buy or sell the securities mentioned.

Important Information

This fund meets the requirements under Article 8 of the EU Sustainable Finance Disclosure Regulation (SFDR); the fund has binding commitments in its investment policy to promote environmental and/or social characteristics and any companies in which it invests should follow good governance practices.

This classification does not represent the fund is authorised as a Green or environmental, social and governance (ESG) fund in Hong Kong. Please visit the full list of SFC-authorised ESG funds at: <https://www.sfc.hk/en/regulatory-functions/products/list-of-esg-funds>.

This material is intended to be of general interest only and should not be construed as investment advice. It does not constitute legal or tax advice and it is not an offer for shares or an invitation to apply for shares of the Luxembourg-domiciled SICAV Franklin Templeton Investment Funds (the "Fund" or "FTIF"). For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the fund and will not be investing directly in the underlying assets of the fund.

Franklin Templeton ("FT") provides no guarantee or assurance that the Fund's investment objective will be attained. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. **Past performance is not an indicator or a guarantee of future performance.** Currency fluctuations may cause the value of a Fund's investments to diminish or increase.

FT shall not be liable to any user of this document or to any other person or entity for the inaccuracy of information or any errors or omissions in its contents, regardless of the cause of such inaccuracy, error or omission. Any opinions expressed are the author's at publication date and they are subject to change without prior notice. Any research and analysis contained in this material has been procured by FT for its own purposes and is provided to you only incidentally. Data from third party sources may have been used in the preparation of this document and FT has not independently verified, validated or audited such data.

No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Shares of the Fund are not available for public distribution in all jurisdictions and prospective investors, who are not financial professionals, should consult their financial advisor before deciding to invest. The Fund may use financial derivatives or other instruments which may entail specific risks more fully described in the Fund's Documents.

Subscriptions to shares of the Fund should only be made on the basis of the Fund's current Prospectus, and, where available, the relevant offering documents.

In addition, a Summary of Investor Rights is available from <https://www.franklintempleton.com.hk/en-hk/about-us/summary-of-investor-rights>. The summary is available in English and Chinese.

The sub-funds of FTIF are notified for marketing in multiple EU Member States under the UCITS Directive. FTIF can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive. Franklin Templeton International Services S.à r.l. – Supervised by the Commission de Surveillance du Secteur Financier.

Performance information is based on the stated share class only, in Fund Currency, NAV to NAV, taking into account of dividend reinvestments and capital gain or loss.

When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.

Hedged share classes will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.

Morningstar ratings are applied at share class level, which means that each share class requires 36 monthly returns before it will be awarded a rating.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.

© Morningstar, Inc. All rights reserved. The information contained here in (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Benchmark: Indices are unmanaged, and one cannot invest directly in an index. They do not reflect any fees, expenses or sales charges. Important data provider notices and terms available at www.franklintempletondatasources.com. Source: Nasdaq OMX.

Hong Kong, Taiwan and Macau: Issued by Franklin Templeton Investments (Asia) Limited, 62/F, Two IFC, 8 Finance Street, Central, Hong Kong.

This document has not been reviewed by the Securities and Futures Commission in Hong Kong or Monetary Authority of Macao in Macau.

This document is intended to be of general interest only. Distribution of this document may be restricted in certain jurisdictions: the document may not be used other than by the distributors in Macau and master agent in Taiwan. For Macau, the document is prepared for the purpose of providing information related to foreign investment funds authorized to be marketed and sold in Macau. Those funds are not domiciled in the Macau Special Administrative Region ("SAR") and that the regulatory standards may differ from those applicable in the Macau SAR. This document should not be construed as individual investment advice or offer or solicitation to buy, sell or hold any shares of fund or security. **Investment involves risks.** Past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD ("other foreign currency"). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.

The data, comments, opinions, estimates and other information contained herein may be subject to change without notice. There is no guarantee that an investment product will meet its objective and any forecasts expressed will be realized. Performance may also be affected by currency fluctuations. Reduced liquidity may have a negative impact on the price of the assets. Currency fluctuations may affect the value of overseas investments. Where an investment product invests in emerging markets, the risks can be greater than in developed markets. Where an investment product invests in a specific sector or geographical area, the returns may be more volatile than a more diversified investment product. The mention of any individual securities should neither constitute nor be construed as a recommendation to purchase or sell securities, and the information provided regarding such individual securities is not a sufficient basis upon which to make an investment decision. Fund allocations, holdings and characteristics are subject to change at any time. Franklin Templeton may have an interest in the acquisition or disposal of the securities mentioned herein.

Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from use of this document or any comment, opinion or estimate herein. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Unless stated otherwise, all information is as of the date of this document. Source: Franklin Templeton.

© 2025 Franklin Templeton. All rights reserved.

Offering Documents



Shareholder Letter

